Cargando…

Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review

Immunocompromised individuals are at high risk of poor coronavirus disease 2019 (COVID-19) outcomes and demonstrate a lower immune response to COVID-19 vaccines, including to the novel mRNA vaccines that have been shown to elicit high neutralizing antibody levels. This review synthesized available d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Napuri, Norka I., Curcio, Daniel, Swerdlow, David L., Srivastava, Amit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132351/ https://www.ncbi.nlm.nih.gov/pubmed/35614299 http://dx.doi.org/10.1007/s40121-022-00648-2

Ejemplares similares

Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
por: Lederer, Katlyn, et al.
Publicado: (2022)

Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients
por: Bader, Guy, et al.
Publicado: (2023)

mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients
por: Azzolini, Elena, et al.
Publicado: (2022)

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
por: Silvestris, Nicola
Publicado: (2021)

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
por: Obeid, Michel, et al.
Publicado: (2022)

Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients
por: Fallet, Benedict, et al.
Publicado: (2023)

Immunoinformatic-guided designing and evaluating protein and mRNA-based vaccines against Cryptococcus neoformans for immunocompromised patients
por: Elalouf, Amir, et al.
Publicado: (2023)

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients
por: Oyaert, Matthijs, et al.
Publicado: (2022)

Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System
por: Tartof, Sara Y., et al.
Publicado: (2023)

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients
por: Solera, Javier T, et al.
Publicado: (2023)

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients
por: Chu, Chang, et al.
Publicado: (2023)

Translation suppression underlies the restrained COVID-19 mRNA vaccine response in the high-risk immunocompromised group
por: Kim, Kangsan, et al.
Publicado: (2022)

Third dose corrects waning immunity to SARS-CoV-2 mRNA vaccines in immunocompromised patients with immune-mediated inflammatory diseases
por: Cheung, Michelle W, et al.
Publicado: (2022)

Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals
por: Healy, Katie, et al.
Publicado: (2022)

Heterogenous antibody and T‐cell responses to SARS‐CoV‐2 mRNA vaccines among immunocompromised young people
por: Lu, Liangjian, et al.
Publicado: (2023)

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
por: Blixt, Lisa, et al.
Publicado: (2022)

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
por: Rahav, Galia, et al.
Publicado: (2021)

Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis
por: Mehrabi Nejad, Mohammad-Mehdi, et al.
Publicado: (2022)

Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients
por: Baron, Frédéric, et al.
Publicado: (2022)

Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide survey
por: Shapiro Ben David, Shirley, et al.
Publicado: (2021)

Innate immune mechanisms of mRNA vaccines
por: Verbeke, Rein, et al.
Publicado: (2022)

Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans
por: Cagigi, Alberto, et al.
Publicado: (2021)

An mRNA vaccine elicits STING-dependent antitumor immune responses
por: Chen, Zhe, et al.
Publicado: (2023)

Analyzing immune responses to varied mRNA and protein vaccine sequences
por: Park, Hyeong-Jun, et al.
Publicado: (2023)

NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
por: Cuapio, Angelica, et al.
Publicado: (2022)

mRNA-Based Vaccines
por: Kowalzik, Frank, et al.
Publicado: (2021)

Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents
por: Kim, Yoo-Yeon, et al.
Publicado: (2022)

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
por: Hofsink, Quincy, et al.
Publicado: (2023)

Vaccine Response in the Immunocompromised Patient with Focus on Cellular Immunity
por: Bahrs, Christina, et al.
Publicado: (2022)

Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune-modifying therapies
por: Klebanoff, Samuel D., et al.
Publicado: (2023)

Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development
por: Wu, Changwu, et al.
Publicado: (2022)

Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals
por: Fraley, Elizabeth, et al.
Publicado: (2021)

Dangers of mRNA vaccines
por: Ali, Tahoora, et al.
Publicado: (2021)

A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®
por: Speich, Benjamin, et al.
Publicado: (2021)

Influenza Viruses: Innate Immunity and mRNA Vaccines
por: Lee, SangJoon, et al.
Publicado: (2021)

Immune Response to COVID-19 mRNA Vaccine—A Pilot Study
por: Lange, Andrzej, et al.
Publicado: (2021)

Durability of immune responses to mRNA booster vaccination against COVID-19
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
por: Zhang, Biyan, et al.
Publicado: (2022)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals
por: Ainsua-Enrich, Erola, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_anushg6jbl2o9bkq1cirpp10q2